학술논문
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
Document Type
Article
Author
Ahn, Myung-Ju; Han, Ji-Youn; Lee, Ki Hyeong; Kim, Sang-We; Kim, Dong-Wan; Lee, Yun-Gyoo; Cho, Eun Kyung; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Jong-Seok; Min, Young Joo; Kim, Jin-Soo; Lee, Sung Sook; Kim, Hye Ryun; Hong, Min Hee; Ahn, Jin Seok; Sun, Jong-Mu; Kim, Heung Tae; Lee, Dae Ho; Kim, Sohee; Cho, Byoung Chul
Source
In The Lancet Oncology December 2019 20(12):1681-1690
Subject
Language
ISSN
1470-2045